Drugs / Chlorhexidine gluconate
last change 4 days ago re-read 2 minutes ago

Chlorhexidine gluconate

Other / unclassified

Developed for
nosocomial infection · gingivitis · periodontitis · bacterial infectious disease · dental caries · methicillin-resistant staphylococcus aureus infectious disease · staphylococcus aureus infection · COVID-19
+40 more · cystic fibrosis · HIV infectious disease · infectious disease · infectious disease with sepsis · periodontal disorder · periprosthetic joint infection · pneumonia · respiratory tract infectious disorder · smooth surface dental caries · urinary tract infection · abscess · bacterial pneumonia · Clostridium difficile colitis · endometritis · Enterococcus infectious disease · gingival recession · impacted teeth, multiple · mouth mucosa disorder · mucositis · neonatal sepsis · oral candidiasis · periapical periodontitis · periodontitis, chronic, adult · pharyngitis · primary bacterial infectious disease · prosthesis-related infectious disease · pulmonary hypertension · soft tissue sarcoma · tracheobronchitis · ulcer of lower limbs · ulcerative stomatitis · vulvovaginal candidiasis · acne · dental pulp necrosis · disease related to hematopoietic stem cell transplant · gingival disorder · skin infection · staphylococcal infection · suppurative periapical periodontitis · ulcer disease
Investigated by
Medline Industries · 3M · Sage Products, Inc. · C. R. Bard · Centers for Disease Control and Prevention · Children's Hospital of Philadelphia
+140 more · Dexcel Pharma Technologies Ltd. · Solventum US LLC · University of Guanajuato · University of North Carolina, Chapel Hill · University of Washington · Washington University School of Medicine · Baylor College of Medicine · Boston University · Cook Children's Medical Center · Federal University of Rio Grande do Norte · GlaxoSmithKline · King Abdulaziz University · McMaster University · Molnlycke Health Care AB · National Cheng-Kung University Hospital · Northwestern University · St. Louis Children's Hospital · State University of New York at Buffalo · São Paulo Research Foundation · University of Alabama at Birmingham · University of Michigan · University of Pennsylvania · University of Texas Southwestern Medical Center · Zambia Center for Applied Health Research and Development · Academic Medical Center - University of Amsterdam · Adam Olson · Agency for Healthcare Research and Quality (AHRQ) · Alberta Health services · Anam Sattar · Angela Bianco · Ankara University · Antisepsia Central · Aqsa Afzal · Assistance Publique Hopitaux De Marseille · Aydin Adnan Menderes University · Bill and Melinda Gates Foundation · BioScience Laboratories, Inc. · Botswana-UPenn Partnership · CF Therapeutics Development Network Coordinating Center · Caroline Scott · Celeste Chandonnet · Centro Ortopedico y Quirurgico del Pie · Charles University, Czech Republic · Children's Hospital Medical Center, Cincinnati · Colgate Palmolive · Columbia University · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Cook County Health · Dentaid SL · E-DA Hospital · Faculty Hospital Kralovske Vinohrady · Federal Teaching Hospital Abakaliki · Federal University of São Paulo · Gabriel John Culbert · Gladwin, Mark, MD · Göteborg University · HaEmek Medical Center, Israel · Hamilton Health Sciences Corporation · Harran University · Henry M. Jackson Foundation for the Advancement of Military Medicine · Hyagriv Simhan · Imperial College London · Indiana University · Istanbul University - Cerrahpasa · Jared Brooks · Johns Hopkins Bloomberg School of Public Health · Johns Hopkins University · Joseph Kim · Karabuk University · Karolinska Institutet · King Edward Memorial Hospital · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · M.D. Anderson Cancer Center · Medical University of Silesia · all 146 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) DYNA-HEX 2 1989-12-27 – 2003-12-19 fda.gov
Label expansion US (FDA) HIBICLENS 1982-03-01 fda.gov
Approved US (FDA) HIBICLENS 1976-09-17 fda.gov

Trials 109 · started per year

today
US approved 1976
2
2
2
6
1
2
6
6
5
3
9
10
3
8
6
3
6
7
6
6
4
4
1
197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 18 trials
Phase 1 NCT03787082 Dec 2022 → Dec 2023 diastolic heart failure, pulmonary hypertension Gladwin, Mark, MD Withdrawn No outcome recorded
Phase 1 NCT03331263 Jul → Aug 2017 Medline Industries Completed No outcome recorded
Phase 1 NCT02326467 Feb 2016 → Sep 2018 drug pseudoallergy, exanthem, infectious disease Celeste Chandonnet Completed No outcome recorded
Phase 1 NCT02001311 Jan → Apr 2014 dental caries, malposition of teeth with or without hypodontia/oligodontia King Abdulaziz University Unknown No outcome recorded
Phase 1 NCT02337192 Jan → Jun 2014 University of Sao Paulo Completed No outcome recorded
Phase 1 NCT01036412 Dec 2009 → Aug 2012 head and neck cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT00130221 Jun 2005 → Jun 2006 Clostridium infectious disease, infectious disease with sepsis, nosocomial infection, pneumonia +1 Cook County Health Completed No outcome recorded
Phase 1 NCT01083407 Jun 2005 → Jun 2006 Federal University of São Paulo Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03004196 Sep → Oct 2015 smooth surface dental caries Peoples University, Bhanpur, Bhopal Completed No outcome recorded
Phase 219 trials
Phase 2 NCT06712433 Sep 2026 → Sep 2028 expected soft tissue sarcoma Adam Olson Not yet recruiting No outcome recorded
Phase 2 NCT05709015 Jan → Feb 2023 gingivitis University of Ljubljana Completed No outcome recorded
Phase 2 NCT05059145 Apr 2022 → Dec 2024 vulvovaginal candidiasis Karolinska Institutet Unknown No outcome recorded
Phase 2 NCT05090657 Feb → Aug 2022 nosocomial infection Ondine Biomedical Inc. Completed No outcome recorded
Phase 2 NCT03423147 Oct 2018 → Feb 2021 nosocomial infection Angela Bianco Terminated No outcome recorded
Phase 2 NCT03489629 Apr 2018 → Sep 2025 cystic fibrosis University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 2 NCT03681990 Jun → Jul 2017 Solventum US LLC Completed No outcome recorded
Phase 2 NCT03326726 Nov 2016 Medline Industries Completed No outcome recorded
Phase 2 NCT04830969 Nov 2016 → Jan 2021 periodontitis, type 2 diabetes mellitus State University of New York at Buffalo Completed No outcome recorded
Phase 2 NCT02589067 Oct 2015 → Oct 2017 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Completed No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT01241318 Feb 2011 → Sep 2013 infectious disease with sepsis Boston University Completed No outcome recorded
Phase 2/3 NCT00549393 Feb 2008 → Dec 2010 nosocomial infection Johns Hopkins University Completed No outcome recorded
Phase 2/3 NCT00516906 Oct → Dec 2007 Solventum US LLC Completed No outcome recorded
Phase 2/3 NCT00272675 Aug 2003 → Sep 2005 nosocomial infection, respiratory tract infectious disorder Academic Medical Center - University of Amsterdam Completed No outcome recorded
Phase 318 trials
Phase 3 NCT06126614 May 2024 → Nov 2028 expected periprosthetic joint infection Hamilton Health Sciences Corporation Recruiting No outcome recorded
Phase 3 NCT07142408 Mar 2023 → Oct 2030 expected The Cooper Health System Recruiting No outcome recorded
Phase 3 NCT04218110 Feb → Mar 2020 Professional Disposables International, Inc. Completed No outcome recorded
Phase 3 NCT04048356 Jul 2019 → Feb 2021 female reproductive system disorder, pelvic organ prolapse, urinary tract infection University of New Mexico Completed No outcome recorded
Phase 3 NCT03442023 Feb → Nov 2019 University of Guanajuato Unknown No outcome recorded
Phase 3 NCT02490631 Aug 2015 → Dec 2018 Vanderbilt University Completed No outcome recorded
Phase 3 NCT02526667 Aug → Dec 2015 Medline Industries Completed No outcome recorded
Phase 3 NCT02291601 Oct 2014 → Sep 2015 Medline Industries Completed No outcome recorded
Phase 3 NCT02224625 Aug 2014 → Jun 2015 Medline Industries Completed No outcome recorded
Phase 3 NCT02222896 Aug → Nov 2014 Medline Industries Completed No outcome recorded
Phase 431 trials
Phase 4 NCT06942026 Apr → May 2025 overdue mouth mucosa disorder Aydin Adnan Menderes University Not yet recruiting No outcome recorded
Phase 4 NCT07203326 Feb 2025 → Aug 2026 overdue gingival recession Ohio State University Active not recruiting No outcome recorded
Phase 4 NCT06210594 Apr 2024 → Nov 2025 staphylococcus aureus infection Johns Hopkins Bloomberg School of Public Health Completed No outcome recorded
Phase 4 NCT05920122 Oct 2023 → Oct 2025 Hyagriv Simhan Completed No outcome recorded
Phase 4 NCT04941131 May → Jul 2023 COVID-19 King Abdulaziz University Completed No outcome recorded
Phase 4 NCT05303805 May 2022 → Apr 2026 overdue ulcer of lower limbs Charles University, Czech Republic Recruiting No outcome recorded
Phase 4 NCT06144983 Feb → Sep 2022 impacted teeth, multiple University of Baghdad Completed No outcome recorded
Phase 4 NCT04954313 Sep 2021 → Feb 2025 cardiovascular disorder, type 2 diabetes mellitus University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 4 NCT03938467 Mar 2021 → Jul 2023 Orthopaedic Associates of Michigan, PC Completed No outcome recorded
Phase 4 NCT04718922 Jan → Jun 2021 Seoul National University Hospital Completed No outcome recorded
Phase not applicable28 trials
NCT07252258 Jul 2025 → Feb 2026 overdue periapical periodontitis Aqsa Afzal Active not recruiting No outcome recorded
NCT06590675 Feb → Mar 2025 primary bacterial infectious disease University of Pennsylvania Terminated No outcome recorded
NCT07364435 Sep 2024 → Jan 2025 Enterococcus infectious disease Özkan Kasap Completed No outcome recorded
NCT06464770 Aug 2024 → Dec 2026 expected periprosthetic joint infection University of Washington Recruiting No outcome recorded
NCT06305546 Apr → Oct 2023 gingivitis Anam Sattar Completed No outcome recorded
NCT06531720 Jan → Dec 2023 ulcerative stomatitis Medical University of Silesia Completed No outcome recorded
NCT06691841 Sep 2022 → May 2023 Shanghai 10th People's Hospital Completed No outcome recorded
NCT05120739 Nov 2021 → May 2023 University Hospital, Grenoble Completed No outcome recorded
NCT04723446 May → Oct 2021 COVID-19 Queen Mary University of London Completed No outcome recorded
NCT06284174 Jan 2021 → Dec 2024 overdue National Cheng-Kung University Hospital Recruiting No outcome recorded
Also used as a comparator or background therapy in 59 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03410602 Comparator Apr 2016 → Aug 2017 periodontitis Meenakshi Ammal Dental College and Hospital Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03115892 Comparator Apr → Sep 2017 Cairo University Unknown No outcome recorded
Phase 27 trials
Phase 2 NCT06690814 Comparator Oct → Nov 2024 skin infection, ulcer disease Fight AIDS and Infectious Diseases Foundation Completed No outcome recorded
Phase 2 NCT04748783 Comparator Mar → Apr 2021 COVID-19 University of North Carolina, Chapel Hill Terminated No outcome recorded
Phase 2 NCT03030989 Comparator Jan 2017 → Jan 2019 disease related to hematopoietic stem cell transplant University of Chicago Completed No outcome recorded
Phase 2 NCT03140254 Comparator Sep 2016 → Mar 2017 C. R. Bard Completed No outcome recorded
Phase 2 NCT02598778 Comparator Nov 2015 → Apr 2016 dental caries Montefiore Medical Center Terminated No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02943759 Comparator Dec 2016 → Feb 2018 suppurative periapical periodontitis Cairo University Completed No outcome recorded
Phase 39 trials
Phase 3 NCT05110001 Background Aug 2022 → Dec 2024 Acanthamoeba keratitis, fungal keratitis University of California, San Francisco Completed No outcome recorded
Phase 3 NCT04756804 Comparator Jun 2021 → Sep 2022 Zurex Pharma, Inc. Completed No outcome recorded
Phase 3 NCT02848482 Background May 2017 → May 2019 periodontal disorder Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Completed No outcome recorded
Phase 3 NCT03061916 Comparator Mar → May 2017 dental caries Cairo University Unknown No outcome recorded
Phase 3 NCT01495117 Comparator Oct 2011 → Oct 2014 Seung Duk Lee Completed No outcome recorded
Phase 420 trials
Phase 4 NCT05586776 Comparator Jan 2023 → Jan 2027 expected University of California, Irvine Recruiting No outcome recorded
Phase 4 NCT07489924 Comparator Jan 2023 → Jul 2025 overdue periodontitis, type 2 diabetes mellitus University of Colima Active not recruiting No outcome recorded
Phase 4 NCT05408923 Comparator Jul 2022 → Jul 2025 spondylosis University of Missouri-Columbia Withdrawn No outcome recorded
Phase 4 NCT05401292 Comparator Feb 2022 → Dec 2026 expected University of Missouri-Columbia Recruiting No outcome recorded
Phase 4 NCT04942496 Comparator Jun 2021 irritant dermatitis Molnlycke Health Care AB Unknown No outcome recorded
Phase not applicable20 trials
NCT07529444 Comparator Mar 2026 → Mar 2027 expected periodontal disorder University of Zagreb Recruiting No outcome recorded
NCT06731881 Background Jun 2025 → Jun 2026 overdue nasal disorder Guy's and St Thomas' NHS Foundation Trust Recruiting No outcome recorded
NCT07180498 Comparator Apr → Oct 2025 overdue periodontal disorder Harran University Recruiting No outcome recorded
NCT06521112 Background May → Jul 2023 mucositis TC Erciyes University Completed No outcome recorded
NCT05816512 Comparator Apr → Sep 2023 dental caries, gingivitis, periodontitis Ahmed Yousif Mahdi Unknown No outcome recorded

Evidence & citations 27 cited values

Every value below carries the sentence it was read from. 176 sources stand behind the page.

FieldValueCited text
Known as Chlorhexidine Gluconate “Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface...” NCT01321125
143

Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS...” NCT01232231

“PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4,...” NCT01079663

“The purpose of this study is to assess the efficacy and the safety of Chlorhexidine Gluconate Chip (PerioChip®) in frequent treatment versus routine treatment in therapy of...” NCT01249846

“Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic...” NCT01717690

“3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.” NCT01563406

“The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).” NCT04954313

“Patients were randomly assigned to use 2% chlorhexidine gluconate-impregnated cloths (treatment group) or to shower with soap and water before surgery (control group).” PMID 21612945 May 2011

“A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.” NCT06731881

“Participants were randomly assigned to receive oral care with ozonated water, hypochlorous acid, or 0.12% chlorhexidine gluconate.” PMID 41853915 Mar 2026

“Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation” NCT01472549

Chlorhexidine gluconate 2% vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.” NCT04048356

Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially” NCT00799812

“intranasal mupirocin ointment twice daily for 7 days and chlorhexidine gluconate on the first and last day” PMID 27465112 Jul 2016

“Chloraprep® (chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; Enturia Inc., Leawood, KS, USA)” NCT00739583

Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin” NCT03681990

“0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent” NCT03410602

“The choice of antiseptic agent, povidone iodine or chlorhexidine gluconate, remains debated.” PMID 38884982 Aug 2024

“Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation.” NCT03938467

Chlorhexidine gluconate (CHG) impregnated cloths in this indication.” PMID 41291848 Nov 2025

Chlorhexidine gluconate liquid soap for bathing daily.” NCT02182115

Chlorhexidine gluconate 2% / Isopropyl alcohol 70%” NCT02447497

“2% Chlorhexidine GluconateNCT02385708

Chlorhexidine GluconateNCT02224625

Chlorhexidine GluconateNCT03326726

NCT06531720

NCT03588351

NCT07529444

NCT06521112

NCT03030989

NCT07364435

NCT01105767

NCT03574246

NCT02526667

NCT06305546

NCT03331263

NCT03859908

NCT04942496

NCT00692484

NCT04821193

NCT04603794

NCT02386592

NCT07365956

NCT04756804

NCT01349192

NCT07180498

NCT05816512

NCT02154594

NCT03656588

NCT02215473

NCT06733506

NCT00549393

NCT03385304

NCT05059145

NCT01537783

NCT03423147

NCT01036412

NCT01024738

NCT02490631

NCT04021524

NCT03442023

NCT00867035

NCT07610603

NCT06590675

NCT00636480

NCT01919593

NCT03119831

NCT03061916

NCT01382446

NCT00272675

NCT04505202

NCT06284174

NCT03133312

NCT00066950

NCT01495117

NCT00859235

NCT04830969

NCT02502682

NCT02589067

NCT02326467

NCT06210594

NCT02598778

NCT00002431

NCT05090657

NCT02216227

NCT07466992

NCT04235985

NCT01216761

NCT06464770

NCT00123123

NCT05920122

NCT04654182

NCT01857804

NCT03401749

NCT06144983

NCT00516906

NCT02709824

NCT06936475

NCT04718922

NCT02001311

NCT04483063

NCT02943759

NCT03489629

NCT01594827

NCT01613365

NCT01893060

NCT02029872

NCT00130221

NCT06691841

NCT05408923

NCT06126614

NCT02222896

NCT03140254

NCT00908817

NCT02605382

NCT05110001

NCT02080403

NCT02291601

NCT04218110

NCT03305159

NCT00759187

NCT06712433

NCT01782573

NCT01640925

NCT03209466

NCT00610324

NCT07689695

NCT01233050

NCT02446158

NCT00475930

NCT02433899

NCT02433912

NCT00765167

NCT01241318

NCT02513784

NCT00779246

NCT02337192

NCT07142408

NCT03118232

NCT02639377

NCT01030666

NCT05586776

NCT03014778

NCT00006075

Known as Antigerm Solution “application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab” NCT02446158
Known as CHG “The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during...” NCT05059145
21

“The purpose of this study is to determine whether daily bathing with 2% chlorhexidine gluconate-impregnated antiseptic cleanser (CHG) significantly reduces incidence of...” NCT01717690

“OBJECTIVE: To determine whether patients bathed daily with chlorhexidine gluconate (CHG) have a lower incidence of primary bloodstream infections (BSIs) compared with patients...” PMID 17954801 Oct 2007

“We hypothesized that oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate (CHG) would be an effective method to reduce these complications as reported...” PMID 29671041 Apr 2018

“This study will evaluate the amount of chlorhexidine gluconate (CHG) present on treated skin of human volunteers following different application times with a test material...” NCT04235985

“personal hygiene measures, including chlorhexidine (CHG) body wash, did not prevent overall and methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue...” PMID 25421482 Nov 2014

“Our objective was to assess whether daily bathing in chlorhexidine gluconate (CHG) compared with standard bathing practices would reduce bacteraemia in critically ill children.” PMID 23363666 Jan 2013

“Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)” NCT00739583

“2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHGNCT01216761

“Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially” NCT00799812

“Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.” NCT02447497

“Chlorhexidine gluconate (CHG) is a cationic bisguanide that works through disruption of cell membranes.” NCT06733506

“2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering.” NCT03118232

“Chlorhexidine gluconate (CHG) impregnated cloths in this indication.” PMID 41291848 Nov 2025

“0.05% chlorhexidine gluconate (CHG) solution for soaking the wound” NCT06284174

“2% chlorhexidine gluconate (CHG) impregnated cloths” NCT00475930

“4% chlorhexidine gluconate (CHG) in purified water” NCT03385304

“0.2% chlorhexidine gluconate (CHG) solution” NCT00610324

“chlorhexidine gluconate [CHG] bathing” PMID 30037355 Jul 2018

“Chlorhexidine Gluconate in IMS, CHGNCT02216227

“Chlorhexidine gluconate (CHG)” NCT02386592

“Chlorhexidine Gluconate (CHG)” NCT06590675

Known as ChloraPrep “The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical...” NCT01321125
Known as chlorhexidine “Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and...” NCT01105767
Known as Chlorhexidine Digluconate “The standard therapy used in the control group will use only Cyteal TM lavage solution, which contains hexamidine diisetione 100 mg in 100 ml, chlorhexidine digluconate 20%...” NCT05303805
16

“Hand antisepsis by scrub Surgical Hand scrubbing using chlorhexidine digluconate with the addition of an alcoholic solution of chlorhexidine digluconate and potassium sorbate.” NCT04454619

“0.12% Chlorhexidine Digluconate and 0.05% Cetylpyridinium Chloride vs Probiotics (Lactobacillus Reuteri Prodentis) on Porphyromonas Gingivalis.” NCT07489924

“new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX)” NCT02194023

“0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.” NCT02848482

NCT07309679

NCT04683146

NCT04723446

NCT01962493

NCT06690814

NCT07252258

NCT05709015

NCT01083407

NCT02319668

NCT01014143

NCT01751178

NCT04941131

Known as Chlorhexidine Gluconate in IMS Chlorhexidine Gluconate in IMS, CHG” NCT02216227
Known as Chlorhexidine Gluconate in IMS, CHG Chlorhexidine Gluconate in IMS, CHGNCT02216227
Known as Chlorhexidine Gluconate Mouthwash ClinicalTrials.gov intervention name — accepted as the source's own label NCT03787082
Known as Chlorhexidine mouthwash ClinicalTrials.gov intervention name — accepted as the source's own label NCT03115892
Known as chlorohexidine chlorohexidine mouthwash take two times per day for one week” NCT03115892
Known as chorhexidine digluconate “The aim of the study was comparing the effectiveness of oral mucosa healing properties of different preparations: CHX=0,2% chorhexidine digluconate, CHS=8,7% choline...” NCT06531720
Known as CHX “The aim of the study was comparing the effectiveness of oral mucosa healing properties of different preparations: CHX=0,2% chorhexidine digluconate, CHS=8,7% choline...” NCT06531720
3

“new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX)” NCT02194023

“rinsing with: Group 1-0.2% Chlorhexidine digluconate (CHX); Group 2-1.5% Hydrogen peroxide (H2O2);” PMID 37542087 Aug 2023

“such as those containing chlorhexidine digluconate (CHX)” PMID 27557865 Aug 2016

Known as Clorhexidine digluconate “Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)” NCT02194023
Known as Dr. Reddy's Clohex ClinicalTrials.gov intervention name — accepted as the source's own label NCT03004196
Known as DynaHex DynaHex (2% CHG)” NCT02224625
Known as HEXIDINE “0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent” NCT03410602
Known as Hibiclens “Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and...” NCT01105767
2

NCT05401292

NCT03372122

Known as Kloroben “Commercially available 0.2% chlorhexidine gluconate mouthrinse (Kloroben®, Drogsan, Ankara, Türkiye).” NCT07689695
Known as MicroDerm ClinicalTrials.gov intervention name — accepted as the source's own label NCT07203326
Known as Perio-Aid Treatment Perio-Aid TreatmentNCT02194023
Known as PerioChip “The purpose of this study is to assess the efficacy and the safety of Chlorhexidine Gluconate Chip (PerioChip®) in frequent treatment versus routine treatment in therapy of...” NCT01249846
1

“Chlorhexidine Gluconate chip (Periochip®)” NCT01079663

Known as Periogard ClinicalTrials.gov intervention name — accepted as the source's own label NCT04748783
Known as ReadyPrep CHG “Single Dose Pharmacokinetic Study to Assess the Systemic Exposure of Chlorhexidine From ReadyPrep® CHG (2% Chlorhexidine Gluconate Cloth)” NCT03331263
Known as Softasept “CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG)” NCT03685604